Summary
45.30 -0.20(-0.44%)08/28/2024
ENOV (ENOV)
ENOV (ENOV)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.44 | 1.85 | 4.77 | 34.87 | -6.79 | -2.18 | 0.00 | 500.50 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 45.30 | |
| Open | 45.16 | |
| High | 46.02 | |
| Low | 44.92 | |
| Volume | 307,636 | |
| Change | -0.20 | |
| Change % | -0.44 | |
| Avg Volume (20 Days) | 416,221 | |
| Volume/Avg Volume (20 Days) Ratio | 0.74 | |
| 52 Week Range | 43.04 - 66.71 | |
| Price vs 52 Week High | -32.09% | |
| Price vs 52 Week Low | 5.25% | |
| Range | 0.02 | |
| Gap Up/Down | -0.58 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,531 | |
| EBIDTA | 597,830,016 | |
| PE Ratio | 50.5263 | |
| PEG Ratio | 1.0958 | |
| WallStreet Target Price | 140.00 | |
| Book Value | 88.6540 | |
| Earnings Per Share | 1.3680 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 7.1400 | |
| EPS Estimate Next Year | 8.1400 | |
| Diluted EPS (TTM) | 1.3680 | |
| Revenues | ||
| Profit Marging | 0.0186 | |
| Operating Marging (TTM) | 0.0876 | |
| Return on asset (TTM) | 0.0266 | |
| Return on equity (TTM) | 0.0239 | |
| Revenue TTM | 3,854,302,976 | |
| Revenue per share TTM | 75.3660 | |
| Quarterly Revenue Growth (YOY) | 0.2360 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 1,618,887,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 50.5263 | |
| Forward PE | 16.1290 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.3648 | |
| Revenue Enterprise Value | 2.0385 | |
| EBITDA Enterprise Value | 15.6856 | |
| Shares | ||
| Shares Outstanding | 53,776,700 | |
| Shares Float | 47,462,863 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 11.90 | |
| Institutions (%) | 90.90 | |
08/20 12:56 EST - zacks.com
Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene
Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.
Enovis (ENOV) Introduces STAR Ankle With e+ Polyethylene
Enovis (ENOV) brings the first mobile-bearing ankle system with e+ Polyethylene, which offers enhanced durability, stability and longevity for improved patient outcomes.
08/20 08:00 EST - globenewswire.com
Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures
First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller. First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller.
Enovis Continues to Redefine Revision Knee Surgery with the Addition of EMPOWR™ Cones to EMPOWR Revision Knee™, Creating a Comprehensive Portfolio for Efficient Revision Procedures
First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller. First surgeries using EMPOWR Revision Knee™ with EMPOWR™ Cones successfully completed by design consultants Dr. Beau Kildow and Dr. Leonard T. Buller.
08/19 08:00 EST - globenewswire.com
Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability
Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert
Enovis™ Introduces STAR® Ankle, now with e+™ Polyethylene for Unmatched Durability
Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert Revolutionary Scandinavian Total Ankle Replacement (STAR® Ankle) System Now Includes Vitamin E-Blended Polyethylene Insert
08/12 16:10 EST - globenewswire.com
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
08/07 08:16 EST - zacks.com
Enovis (ENOV) Q2 Earnings Top Estimates
Enovis (ENOV) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.61 per share a year ago.
Enovis (ENOV) Q2 Earnings Top Estimates
Enovis (ENOV) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.61 per share a year ago.
08/07 06:00 EST - globenewswire.com
Enovis Announces Second Quarter 2024 Results
Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 28, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:00 am ET.
Enovis Announces Second Quarter 2024 Results
Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended June 28, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:00 am ET.
07/31 11:06 EST - zacks.com
Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Enovis (ENOV) to Report a Decline in Earnings: What to Look Out for
Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/25 06:00 EST - globenewswire.com
Enovis Announces Time Change for Second Quarter 2024 Results Conference Call
Wilmington, DE, July 25, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced a change in the scheduling of its upcoming earnings results conference call. The call will still take place on August 7, 2024, but will now be held at 8:00 a.m. Eastern Time, instead of the previously announced time. There is no change to the date, the dial-in or webcasting information. A presentation related to the call will be available on ir.enovis.com.
Enovis Announces Time Change for Second Quarter 2024 Results Conference Call
Wilmington, DE, July 25, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced a change in the scheduling of its upcoming earnings results conference call. The call will still take place on August 7, 2024, but will now be held at 8:00 a.m. Eastern Time, instead of the previously announced time. There is no change to the date, the dial-in or webcasting information. A presentation related to the call will be available on ir.enovis.com.
07/16 07:00 EST - globenewswire.com
Enovis to Host Second Quarter 2024 Results Conference Call on August 7th
Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com.
Enovis to Host Second Quarter 2024 Results Conference Call on August 7th
Wilmington, DE, July 16, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2024 financial results on Wednesday, August 7, 2024 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call will be available on ir.enovis.com.
07/15 11:26 EST - zacks.com
Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.
Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis
Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.
07/15 07:27 EST - zacks.com
Bet on 3 Top-Ranked Stocks With Rising P/E
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Energizer (ENR), Super League Enterprise Inc. (SLE) and Enovis (ENOV).
Bet on 3 Top-Ranked Stocks With Rising P/E
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Energizer (ENR), Super League Enterprise Inc. (SLE) and Enovis (ENOV).
07/15 00:58 EST - seekingalpha.com
Enovis Languishing Despite Respectable Performance
Enovis stock performance has continued to lag larger sector peers despite respectable results from the Reconstructive (orthopedic device) business. The Street may well be concerned that Enovis cannot compete long term with rivals that offer robotic systems (and implants designed for those robotic systems). Robotic system competition is indeed a threat, particularly if robotic systems move into shoulder surgeries in a big way, but Enovis has a strong competitive position in the ambulatory segment.
Enovis Languishing Despite Respectable Performance
Enovis stock performance has continued to lag larger sector peers despite respectable results from the Reconstructive (orthopedic device) business. The Street may well be concerned that Enovis cannot compete long term with rivals that offer robotic systems (and implants designed for those robotic systems). Robotic system competition is indeed a threat, particularly if robotic systems move into shoulder surgeries in a big way, but Enovis has a strong competitive position in the ambulatory segment.
07/12 08:00 EST - globenewswire.com
Enovis™ Releases AltiVate Reverse® Glenoid System, Widening Range of Patients Who May be Treated with AltiVate Reverse®
New full-range solution adds bone-sparing baseplate, peripheral fixation, and glenosphere options to proven reverse shoulder prosthesis (RSP®) glenoid baseplate while maintaining hallmark simplicity and efficiency. First surgery using AltiVate Reverse® Glenoid System conducted by Dr. Mark Frankle at Tampa General Hospital on Monday, July 8, 2024. New full-range solution adds bone-sparing baseplate, peripheral fixation, and glenosphere options to proven reverse shoulder prosthesis (RSP®) glenoid baseplate while maintaining hallmark simplicity and efficiency. First surgery using AltiVate Reverse® Glenoid System conducted by Dr. Mark Frankle at Tampa General Hospital on Monday, July 8, 2024.
Enovis™ Releases AltiVate Reverse® Glenoid System, Widening Range of Patients Who May be Treated with AltiVate Reverse®
New full-range solution adds bone-sparing baseplate, peripheral fixation, and glenosphere options to proven reverse shoulder prosthesis (RSP®) glenoid baseplate while maintaining hallmark simplicity and efficiency. First surgery using AltiVate Reverse® Glenoid System conducted by Dr. Mark Frankle at Tampa General Hospital on Monday, July 8, 2024. New full-range solution adds bone-sparing baseplate, peripheral fixation, and glenosphere options to proven reverse shoulder prosthesis (RSP®) glenoid baseplate while maintaining hallmark simplicity and efficiency. First surgery using AltiVate Reverse® Glenoid System conducted by Dr. Mark Frankle at Tampa General Hospital on Monday, July 8, 2024.
06/24 09:20 EST - zacks.com
5 Medical Info Systems Stock to Buy for a Stable Portfolio
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
5 Medical Info Systems Stock to Buy for a Stable Portfolio
We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.
06/21 08:22 EST - benzinga.com
Top 3 Health Care Stocks That Could Blast Off In June
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 3 Health Care Stocks That Could Blast Off In June
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
05/28 12:26 EST - zacks.com
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
05/20 01:03 EST - https://www.defenseworld.net
Enovis (NYSE:ENOV) vs. Envoy Medical (NASDAQ:COCH) Financial Survey
Enovis (NYSE:ENOV – Get Free Report) and Envoy Medical (NASDAQ:COCH – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership. Analyst Recommendations This is a breakdown of current ratings and target prices for Enovis and Envoy Medical, as reported by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enovis 0 0 8 0 3.00 Envoy Medical 0 0 2 0 3.00 Enovis presently has a consensus target price of $75.43, indicating a potential upside of 43.92%. Envoy Medical has a consensus target price of $6.00, indicating a potential upside of 92.93%. Given Envoy Medical’s higher possible upside, analysts clearly believe Envoy Medical is more favorable than Enovis. Institutional and Insider Ownership 98.5% of Enovis shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 2.4% of Enovis shares are owned by insiders. Comparatively, 0.7% of Envoy Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Volatility & Risk Enovis has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Profitability This table compares Enovis and Envoy Medical’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Enovis -4.51% 3.98% 2.88% Envoy Medical N/A N/A -112.11% Valuation and Earnings This table compares Enovis and Envoy Medical’s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $1.71 billion 1.68 -$33.26 million ($1.50) -34.94 Envoy Medical $316,000.00 192.90 -$29.91 million N/A N/A Envoy Medical has lower revenue, but higher earnings than Enovis. Summary Enovis beats Envoy Medical on 6 of the 11 factors compared between the two stocks. About Enovis (Get Free Report) Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware. About Envoy Medical (Get Free Report) Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Enovis (NYSE:ENOV) vs. Envoy Medical (NASDAQ:COCH) Financial Survey
Enovis (NYSE:ENOV – Get Free Report) and Envoy Medical (NASDAQ:COCH – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership. Analyst Recommendations This is a breakdown of current ratings and target prices for Enovis and Envoy Medical, as reported by MarketBeat.com. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enovis 0 0 8 0 3.00 Envoy Medical 0 0 2 0 3.00 Enovis presently has a consensus target price of $75.43, indicating a potential upside of 43.92%. Envoy Medical has a consensus target price of $6.00, indicating a potential upside of 92.93%. Given Envoy Medical’s higher possible upside, analysts clearly believe Envoy Medical is more favorable than Enovis. Institutional and Insider Ownership 98.5% of Enovis shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 2.4% of Enovis shares are owned by insiders. Comparatively, 0.7% of Envoy Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Volatility & Risk Enovis has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Profitability This table compares Enovis and Envoy Medical’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Enovis -4.51% 3.98% 2.88% Envoy Medical N/A N/A -112.11% Valuation and Earnings This table compares Enovis and Envoy Medical’s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $1.71 billion 1.68 -$33.26 million ($1.50) -34.94 Envoy Medical $316,000.00 192.90 -$29.91 million N/A N/A Envoy Medical has lower revenue, but higher earnings than Enovis. Summary Enovis beats Envoy Medical on 6 of the 11 factors compared between the two stocks. About Enovis (Get Free Report) Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware. About Envoy Medical (Get Free Report) Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
05/10 09:31 EST - zacks.com
5 Medical Info Systems Stocks to Buy for Stable Returns
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
5 Medical Info Systems Stocks to Buy for Stable Returns
We have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.
05/07 10:36 EST - zacks.com
Here's Why Enovis (ENOV) is Poised for a Turnaround After Losing -17.45% in 4 Weeks
Enovis (ENOV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Enovis (ENOV) is Poised for a Turnaround After Losing -17.45% in 4 Weeks
Enovis (ENOV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.